Market news

Company closes $100M Apotex deal, declares special dividend, and advances key clinical programs including DMD, systemic sclerosis, and IPF.

Cumberland Pharmaceuticals (NASDAQ:CPIX) reported a second-quarter operating loss of $3.1 million as it prepared to transition from a commercial-stage specialty pharmaceutical company into an innovation-focused biopharmaceutical business following the sale of its branded U.S. commercial portfolio to

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company committed to developing new products for rare diseases, announced today that it will provide a company update with second quarter 2026 financial results after the market closes on Tuesday, August 4, 2026.

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company developing new products for rare diseases, announced today that its Board of Directors has authorized and declared a special cash dividend of $1.50 per share of the Company's common stock. The dividend will be payable on July 31, 2026, to the shareholders of record at the close of business on July 23, 2026.